Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: ASPEN PHARMA TRADING LIMITED, 3016 LAKE DRIVE, CITYWEST BUSINESS CAMPUS, DUBLIN 24, IRELAND
Testosterone replacement therapy for male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests.
Testosterone administration may also be used as supportive therapy for female-to-male transsexuals.
In general, the dose should be adjusted to the response of the individual patient.
Usually, one injection of 1ml per 3 weeks is adequate.
Safety and efficacy have not been adequately determined in children and adolescents. Pre-pubertal children treated with Sustanon 250 should be treated with caution (see section 4.4).
Different specialist centres have used doses varying from one injection of 1ml every two weeks to one injection of 1ml every four weeks.
Sustanon 250 should be administered by deep intramuscular injection.
The acute toxicity of testosterone is low.
If symptoms of chronic overdose occur (e.g. polycythaemia, priapism) treatment should be discontinued and after disappearance of the symptoms, be resumed at lower dosage.
3 years.
Store below 30°C
Do not refrigerate or freeze.
Store in the original package in order to protect from light.
Each colourless glass ampoule is filled with 1 ml of Sustanon 250.
A box of Sustanon 250 contains 1 ampoule. Not all pack sizes may be marketed. In correspondence please quote batch number.
Any unused product or waste material should be disposed of in accordance with local requirements.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
